HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma.

AbstractPURPOSE:
To determine if ifosfamide-based chemotherapy (IF) offers a survival benefit to adult patients with primary extremity synovial sarcoma.
PATIENTS AND METHODS:
Prospectively collected patient data from 2 institutions was used to identify all adult patients (>or=16 years) with >or=5 cm, deep, primary, extremity, synovial sarcoma that underwent surgical treatment of cure from 1990 to 2002. A total of 101 patients were identified and the median follow-up for survivors was 58 months. Clinical, pathologic, and treatment variables were analyzed for disease-specific survival (DSS), distant recurrence-free survival (DRFS), and local recurrence-free survival (LRFS).
RESULTS:
Sixty-eight (67%) patients were treated with IF and 33 (33%) patients received no chemotherapy (NoC) for the primary tumor. The characteristics of the IF-treated patients [median tumor size = 7.2 cm; monophasic n = 46 (68%)] were similar to NoC patients [median tumor size = 7 cm; monophasic n = 23 (70%)]. The 4-year DSS of the IF-treated patients was 88% compared with 67% for the NoC patients (P = 0.01). Smaller size (HR = 0.3 per 5-cm decrease, P < 0.0001) and treatment with IF (HR = 0.3 compared with NoC, P = 0.007) were independently associated with an improved DSS. Treatment with IF was independently associated with an improved DRFS (HR = 0.4, P = 0.03) but not associated with an improved LRFS (P = 0.39).
CONCLUSION:
Ifosfamide-based chemotherapy was associated with an improved DSS in adult patients with high-risk, primary, extremity, synovial sarcoma and should be considered in the treatment of such patients.
AuthorsFritz C Eilber, Murray F Brennan, Frederick R Eilber, Jeffery J Eckardt, Stephen R Grobmyer, Elyn Riedel, Charles Forscher, Robert G Maki, Samuel Singer
JournalAnnals of surgery (Ann Surg) Vol. 246 Issue 1 Pg. 105-13 (Jul 2007) ISSN: 0003-4932 [Print] United States
PMID17592298 (Publication Type: Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibiotics, Antineoplastic
  • Antineoplastic Agents, Alkylating
  • Doxorubicin
  • Ifosfamide
Topics
  • Adolescent
  • Adult
  • Aged
  • Antibiotics, Antineoplastic (therapeutic use)
  • Antineoplastic Agents, Alkylating (therapeutic use)
  • Arm
  • Disease-Free Survival
  • Doxorubicin (therapeutic use)
  • Female
  • Follow-Up Studies
  • Humans
  • Ifosfamide (therapeutic use)
  • Leg
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (mortality)
  • Prospective Studies
  • Sarcoma, Synovial (drug therapy, mortality)
  • Survival Rate (trends)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: